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Abstract 1 
Background: Ketogenic Enteral Nutrition (KEN™) is a modification of Blackburn’s 2 
protein-sparing modified fast, using a hypocaloric, ketogenic liquid diet.  The study is 3 
about Ketogenic enteral nutrition (KEN) in overweight and obese patients receiving 4 
short treatment of the nutritional solution as 24-hour infusion. It is a retrospective 5 
analysis that examines safety, weight loss and body composition changes after three 6 
sequential 10-days cycles of KEN therapy. Methods:  Anthropometric and bio-7 
impedance data from 629 patients who underwent KEN were collected before and 8 
after completing a ten-day cycle. The study focuses on the change in outcomes from 9 
the first cycle to the second cycle and from the first cycle to the third cycle. The 10 
following outcomes were explored: weight, waist circumference, BMI, fat mass, lean 11 
mass, dry lean mass, phase angle, wellness marker, water mass as a percentage of 12 
total body weight. Statistical tests were used to test for significant differences between 13 
paired cycle 1 and cycle 2 outcomes and also between paired cycle 1 and cycle 3 14 
outcomes. For normally distributed outcomes, the paired t-test was used. Whereas for 15 
skewed outcomes, the Wilcoxon signed-ranks test was used. Scatter plots were used 16 
to plot percentage of excess weight loss against phase angle. The Pearson’s 17 
correlation coefficient was calculated. Regression analysis for the outcome percent 18 
change in weight from cycle 1 to cycle 2 for phase angle and basal metabolic rate 19 
(BMR )/ Weight ratio as predictors was carried out. Results:  The results suggested 20 
significant changes for all analyzed parameters. There were significant decreases in 21 
weight, waist circumference, BMI, fat mass, lean mass, dry lean mass and phase 22 
angle. Quantitative changes in lean mass and dry lean mass were minor changes with 23 
respect to changes in fat mass. There was also a statistically significant increase in 24 
water mass as a % of total body weight and wellness marker from cycle 1 to cycle 3. 25 
The Pearson’s correlation coefficients r=0.18, p=0.004 and r=22, p=0.04 indicated 26 
changes in cycle 1 and cycle 3 in percentage of weight excess to be significantly, 27 
positively correlated to phase angle. The multivariate linear regression model showed 28 
that for a 1 unit increase in BMR / weight there was a 3.3 percent decrease in percent 29 
change in weight.  KEN treatment was overall well tolerated. Long term results need 30 
to be explored in further controlled studies . Conclusions KEN treatment is safe, well 31 
tolerated and results in rapid fat loss without detriment to dry lean mass 32 
Introduction 33 
The global health burden of obesity continues to rise despite improved public 34 
awareness of the importance of a healthy diet and regular exercise (1-3). Current 35 
treatment options for weight reduction include dietary measures, pharmacotherapy, 36 
endoscopic techniques and bariatric surgery. These are limited on the one hand by 37 
efficacy and long-term sustainability and on the other hand by safety and 38 
accessibility to the general public (4). Bariatric surgery is a valid therapeutic option   39 
(5) however inherently invasive and it should not be the first port of call after the 40 
failure of simple dietary measures (6, 7). Many of the currently available dietary 41 
strategies have not been shown to produce selective fat loss without a significant 42 
change in dry lean mass (4).  43 
Dietary interventions that can produce weight reduction of the order of 5-10% of total 44 
body weight have been shown to reduce obesity-related morbidity (8-12). 45 
Ketogenic Enteral Nutrition (KEN™) is a protein-sparing modified fast that has been 46 
developed in order to achieve rapid, safe, selective fat loss (13-16). Research 47 
studies have challenged the notion that ketogenic diets are harmful and demonstrate 48 
no loss of aerobic performance in athletes as well as obese individuals (18,19). 49 
Lessons learnt from these studies suggest providing electrolyte and fluid 50 
replacement to counteract the natriuretic and kaliuretic effects of a ketogenic diet, 51 
together with adequate protein (0.9-1.2g/kg ideal body weight) can be safely 52 
administered to patients for long periods of time without adverse effect (20). Previous 53 
randomized controlled trials have demonstrated early satiety and significant weight 54 
loss using a low-carbohydrate ketogenic diet over a six- to twelve-month period with 55 
long-term safety and with preservation of lean mass (21-23).  56 
On the basis of these observations, we proposed a system involving the continuous 57 
infusion of a specially formulated nasogastric feed over a ten-day period with a 58 
minimum of ten-day interval between each cycle to avoid the effects of keto-59 
adaptation. The continuous nature of the infusion, as well as the ketogenic effects 60 
produced, and in contrast with bolus feeding, helps to create and maintain a sense of 61 
satiety (24, 25).  62 
Methods  63 
Anthropometric and bio-impedance data from 629 patients who underwent KEN 64 
were collected before and after completing each ten-day cycle. The study focused 65 
retrospectively on the British cohort of patients undergoing a prospective multicenter 66 
pilot study on Ken diet from 2006 to 2017 and were not included in previously 67 
published results (14). In particular the study refers to measurements made in the 68 
first three cycles of treatment. Patients who were responding but incompletely 69 
treated were eligible to continue with further cycles. Exclusion criteria included 70 
pregnancy, type I diabetes mellitus, severe hepatic or renal insufficiency (GFR < 71 
20ml/h), inherited metabolic disorders and age < 16 years. Weight, height, waist and 72 
hip circumference, as well as bio-impedance measurements were carried out  73 
immediately before the beginning of a KEN cycle and ten days following the 74 
completion of a KEN cycle.  75 
Basal metabolic rate-weight ratio was measured at baseline and after each cycle by 76 
indirect calorimetry with a coefficient of variation of <10% was used for accurate 77 
analysis.  78 
Patients repeated the KEN treatment cycle as many times as was required to 79 
achieve their target weight based on bio-impedance data.  80 
The study focuses retrospectively on the change in outcomes from the first cycle to 81 
the second cycle and from the first cycle to the third cycle.  82 
Informed consent was obtained from all individual participants included in the study 83 
and this have been performed in accordance with the ethical standards as laid down 84 
in the 1964 Declaration of Helsinki and its later amendments or comparable ethical 85 
standards. Ethical approval was obtained from the University of Rome La Sapienza 86 
Ethics Committee, patients were self-referred and stratified for age and gender.  87 
The following outcomes were explored:  waist circumference, BMI, fat mass, lean 88 
mass, dry lean mass, phase angle, wellness marker, water mass as a percentage of 89 
total body weight.  The cycle 1, 2 and 3 outcomes were analyzed using descriptive 90 
statistics (either mean and standard deviation, or median and inter-quartile range 91 
depending on the data distribution) summarizing the outcome at each cycle. 92 
Statistical tests were used to test for significant differences between paired cycle 1 93 
and cycle 2 outcomes and also between paired cycle 1 and cycle 3 outcomes. 94 
Where changes in outcomes between timepoints were found to be normally 95 
distributed, the paired t-test was used,  whereas where the changes in outcomes had 96 
skeweddistributions, the Wilcoxon signed-rank test was used.  97 
 Linear regression was used to examine associations between changes in both 98 
phase angle and BMR/weight with percentage weight change Initially the simple 99 
relationship between variables was examined, and subsequently multiple linear 100 
regression was used to re-examine the relationships after adjusting for two pre-101 
specified confounding variables.   102 
A six-French polyurethane nasogastric tube (Pennine, UK) was placed by a trained 103 
nurse or physician. In addition, patients received a medication pack, which included, 104 
multivitamins and polyethylene glycol-based laxatives to ensure daily bowel 105 
movements. Patients were provided with Ketostix™ (Bayer, Switzerland) for daily 106 
urinalysis to assess for evidence of ketonuria. Patients were asked to provide a daily 107 
record of their weight, ketonuria, hunger assessment (subjective scale of 1 to 10), 108 
and bowel movements for the duration of the ten-day cycle. Ketonuria was used as 109 
indirect indicator of ketonemia and was collected for observational reasons only.   At 110 
the end of the KEN cycle, patients attended the clinic for removal of their nasogastric 111 
tubes and repeat anthropometric and bio-impedance measurements. Patients were 112 
asked to adhere to a low-carbohydrate unsupervised diet and attended ten days later 113 
for further anthropometric and bio-impedance measurements. The K1000™ 114 
(Nutrimed 2000, Ancona, Italy) formula provides 65g daily protein (providing 1.2g/kg 115 
ideal body weight) in an electrolyte-rich solution. Carbohydrate and fat intake was 116 
completely restricted for the duration of the cycle.   117 
Four-lead bio-impedance analysis measuring impedance at 5 and 50kHz, resistance 118 
at 50kHz, reactance and phase angle at 50kHz were carried out using the Bodystat™ 119 
1500MDD analyzer (Bodystat, Isle of Man) (30-31).  120 
Results 121 
Results were available for the 50 days encompassing 3 treatment cycles in 629 122 
patients.  The results produced clinically relevant changes for all analyzed 123 
parameters (Tab.1 and 2).  124 
PAUL: could you test collectively (by using ANOVA) differences in cyles 1, 2 and 3?  125 
There were significant decreases in weight, waist circumference, BMI, fat mass, lean 126 
mass, dry lean mass and phase angle. Quantitative changes in lean mass and dry 127 
lean mass were negligible with respect to changes in fat mass. There was also a 128 
statistically significant increase in water mass as a percentage of total body weight 129 
and “wellness marker” from cycle 1 to cycle 3.  130 
There was a significant negative association between change in BMR/weight from 131 
cycle 1 to cycle 2 and percentage change in weight during the same period. 132 
However, this association was no longer significant after adjusting for changes in 133 
waist circumference and fat mass.Change in fat phase angle from cycle 1 to cycle 2 134 
was not associated with percentage weight change  135 
PAUL: Diffence in study outcome in age,-sex or BMI in stratified groups ? 136 
Overweight vs obese (people with BMI >30) 137 
When considering the change from cycle 1 to cycle 3, there was a significant 138 
association between change in BMR/weight and change in weight, which remained 139 
significant after adjusting for changes in phase angle, fat mass and waist 140 
circumference. A one-unit increase in BMR/weight was associated with a 2.4% 141 
reduction in weight. There was no significant association between change in phase 142 
angle from cycle 1 to cycle 3 in the simple analysis. However, after adjustments 143 
greater change in phase angle was associated with a greater weight loss.  144 
PAUL : Univariate linera regression analysis should also be performed for other 145 
counfonsing factors among all variables tested. Associated variables should then be 146 
included in adjustments models. 147 
PAUL: Can cycle 3 be also be tested/included ?  148 
Most patients’ daily activities were not restricted, but many chose to spend their 149 
period of treatment away from the workplace. By the fifth day of treatment, 24% of 150 
patients reported a strong sense of asthenia, despite normal blood pressure levels. 151 
Twelve percent of patients reported a mild sense of hunger (score 2-4 / 10). Twenty-152 
two percent of patients (n=138) were known to have type II diabetes mellitus 153 
receiving treatment for their condition, 92% (n=127) of these patients under KEN 154 
infusion were able to suspend their medication without adverse effect on their 155 
glucose homeostasis. No cases of clinically significant hypoglycemia were reported. 156 
Similarly, 80% of patients on anti-hypertensive medication also were able to suspend 157 
their medication during KEN infusion. Tube displacement and blockage occurred in 158 
3% of cases but did not interrupt completion of the treatment. Patients with mild renal 159 
impairment or on anticoagulant therapy underwent close laboratory monitoring 160 
during treatment and completed KEN treatment successfully without adverse effects. 161 
One patient with renal salt wasting required supplemental sodium chloride to 162 
maintain electrolyte stability. Patients on Warfarin therapy were able to halve the 163 
dose for the duration of KEN treatment, whilst maintaining adequate anticoagulation. 164 
Following KEN treatment, patients gained an average of 0.8kg after each of the ten-165 
day intervals.  166 
Discussion167 
 168 
 169 
  170 
This study was undertaken to investigate the hypothesis that KEN treatment results 171 
in selective fat loss and to assess patient safety and tolerability. Historical controls 172 
would suggest intensive dietetic intervention can achieve 1-2% weight reduction over 173 
a period of ten days. This modified fast provides a total of 205 – 270 calories and the 174 
6kg net weight loss observed in ten days is of the same order of magnitude as 175 
observed following dietetic interventions in healthy and obese individuals over one 176 
year (32).  177 
It might be assumed that such rapid weight loss was the consequence of relative 178 
dehydration, but the hallmark of successful KEN treatment is the phenomenon of 179 
selective fat loss without detriment to dry lean mass.  180 
This effect might be due to the reduction in lipogenesis and increased lipolysis (33, 181 
34).  182 
Nair et al. reported that beta-hydroxybutyrate decreases leucine oxidation and 183 
promotes protein synthesis in human (35). 184 
An other mechanism implicated in preservation of lean mass may be due to interaction 185 
of branched-chain amino acid leucine with the insulin signaling pathway to stimulate 186 
downstream control of protein synthesis, resulting in maintenance of muscle mass 187 
during periods of restricted energy intake but high protein intake (36).  188 
When water mass was expressed as a percentage of body weight in our patients, 189 
there was indeed an observed 1-2% increase after KEN therapy.  190 
The study explored regression analysis of the outcomes percent change in weight from 191 
cycle 1 to cycle 2 for the predictors Phase angle and BMR / Weight. BMR/Weight 192 
showed a statistically significant correlation with percent change in weight in univariate 193 
analysis and multivariate analysis. Phase angle failed as predictor of weight loss in 194 
Ken in multivariate analysis. A proportion of 3:1 increase was reported for BMR/ 195 
Weight compared to percent change in weight in multivariate analysis. This stand to 196 
conclusions that metabolically active lean body tissue increased on a 1:3 basis against 197 
percent weight loss after each Ken cycle.  198 
KEN treatment was well tolerated and the few mild to moderate adverse effects 199 
reported were all classified as reversible (Tab 4).  Despite the placement of a fine-bore 200 
nasogastric feeding tube, KEN treatment may be considered a relatively non-invasive 201 
technique, when compared to weight management strategies such as endoscopic 202 
placement of intragastric balloons, endoscopic restrictive procedures and bariatric 203 
surgery. Tube-related complications, which included tube displacement and occlusion, 204 
were rare and did not lead to treatment failure.  205 
It has been proposed that the mechanism of action of KEN treatment in inducing 206 
continuous satiety is two-fold: the continuous infusion of protein and electrolyte-rich 207 
solution into the small intestine producing continuous release of the satiety hormone 208 
Peptide YY, and the effects of ketogenic metabolism in suppressing hunger (33). 209 
Effects of  keton bodies (KBs) on appetite might  be explained by the reduction in 210 
appetite control hormones, as ghrelin and leptin (16).  211 
Preliminary data on mice suggest a third mechanism based on KEN-related delayed 212 
colonic transit and a subsequent increase in butyrate concentrations as a result of 213 
bacterial fermentation, as this may increase insulin sensitivity.  Stimulation of sweet 214 
taste receptors on the tongue have also been shown to stimulate the release of 215 
insulin, counteracting the effects of ketogenesis (35). 216 
We would like to highlight that ketosis is a physiological mechanism described by the 217 
biochemist Hans Krebs to differentiate it from the pathological keto acidosis seen in 218 
type 1 diabetes. In physiological ketosis ketonemia reaches maximum levels of 7/8 219 
mmol/l (it does not go higher because the central nervous system is able to use KBs 220 
efficiently for energy in place of glucose) (16) 221 
However, the majority of recent studies seem instead to amply demonstrate that the 222 
reduction of carbohydrates to levels that induce physiological ketosis can lead to 223 
significant benefits in blood lipid profile (16) 224 
In summary, individuals with obesity, metabolic syndrome, insulin resistance and type 225 
2 diabetes are likely to see symptomatic as well as objective biochemical 226 
improvements on very low- carbohydrate diet. Glucose control improves not only 227 
because there is less glucose coming in, but also because systemic insulin sensitivity 228 
improves as well. 229 
Current studies are on-going to demonstrate the long-term sustainability of KEN 230 
treatment, which will clearly depend on the lifestyle changes adopted by patients 231 
after completing KEN therapy. Preliminary data suggest (14) 85% sustainability at 232 
one year, i.e. patients regain a mean of 15% of their pre-treatment weight at one 233 
year following completion of the required number of KEN treatment cycles. A ten-fold 234 
reduction in all-cause mortality following KEN treatment has been observed (14). 235 
New strategies are being developed to assist patients in maintaining their rate of 236 
weight reduction between KEN treatment cycles (36,37).  237 
KEN treatment is safe, well tolerated and results in rapid fat loss without detriment to 238 
dry lean mass.  Controlled prospective research studies are warranted to compare 239 
KEN treatment with other more balanced dietary interventions. 240 
Acknowledgements: Authors acknowledge all patients taking part into the study and 241 
Homerton University Hospital Research and Development  (R&D) Department for the 242 
support received. 243 
Author Contribution Statement: CP, RS, AF conceived the study; RS and VL 244 
collected data, PB analyzed data. CP, RS, AF, GC, VL, wrote the paper, CP had 245 
primary responsibility for final content. All authors red and approved the final 246 
manuscript.  247 
Conflict of interests  248 
C. Papadia: None Declared, P. Basset: None Declared, V. Lazarescu: None 249 
Declared, G. Cappello: None Declared, A Forbes: None Declared, R. Shidrawi: 250 
Director of Weight Management Systems Ltd, who are the sole representatives for 251 
KEN in the UK252 
References 
1. Mahmoud Abdelaal, Carel W. Lerox, Neil G Docherty. Morbidity and mortality 
associated with obesity. Ann Transl Med 2017; 5:161  
2. Wang YC, McPherson K, Marsh T, Gortmaker S, Brown M.  Health and 
economic burden of the projected obesity trends in the USA and the UK.  
Lancet 2011; 378(9793): 815-25. 
3.  Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, 
Bonneux L.  Obesity in adulthood and its consequences for life expectancy: a 
life-table analysis. Ann Intern Med 2003; 138:24-32. 
4. Belle S.H, Hyg Ms. C, Berk PD.  Safety and efficacy of bariatric surgery: 
longitudinal assessment of bariatric surgery. Surg Obes Relat Dis. 2007; 3: 
116–126 
5. Ted D. Adams, Lance E. Davidson, Sheldon E., Litwin. Weight and Metabolic 
Outcomes 12 Years after Gastric Bypass. N Engl J Med 2017; 377:1143-1155 
6. Gadgil MD, Chang HY, Richards TM. Laboratory testing for and diagnosis of 
nutritional deficiencies in pregnancy before and after bariatric surgery. J 
Womens Health.  2014; 23: 129–137.  
7. Saltzman E, Karl JP. Nutrient deficiencies after gastric bypass surgery. Annu 
Rev Nutr. 2013; 33:183-203. 
8. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze M.B., Overvad K, et 
al. General and abdominal adiposity and risk of death in Europe. N Engl J 
Med 2008; 359:2105-20. 
9. Grundy S.M. Obesity, Metabolic Syndrome and Cardiovascular Disease. The 
Journal of Clinical Endocrinology & Metabolism 2004;89:2595–2600  
10. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherlicker P., 
Clarke R., Emberson J., Halsey J., et al. Body-mass index and cause-specific 
mortality in 900,000 adults: collaborative analyses of 57 prospective studies. 
Lancet 2009; 373:1083-96. 
11. Obesity: the prevention, identification, assessment and management of 
overweight and obesity in adults and children. NICE clinical guideline CG43 
(2014). 
12. Jackson Y, Dietz WH, Sanders C., Kolbe L.J., Whyte J.J., et al. Summary of 
the 2000 Surgeon General’s listening session: toward a national action plan 
on overweight and obesity. Obesity Res 2002; 10:1299-1305. 
13. Bistrian BR, Sherman M. Results of the treatment of obesity with a protein-
sparing modified fast. Int J Obes 1978; 2:143-8. 
14. Cappello GF, Franceschelli A, Cappello A, De Luca P.  Ketogenic enteral 
nutrition as a treatment for obesity: short term and long term results from 
19,000 patients. Nutrition & Metabolism 2012, 9:96 
15. Papadia C. Metabolic Syndrome & Non Alcoholic Fatty Liver Disease. 
Gastroenterol Hepatol Open Access. 2016 5; 7-8.  
16. Paoli A, Rubini A, JS Volek2 and KA Grimaldi3. Beyond weight loss: a review 
of therapeutic uses of very low carbohydrate (ketogenic) diets. European 
Journal of Clinical Nutrition (2013) 67, 789–796 
17. Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL. The human 
metabolic response to chronic ketosis without caloric restriction: preservation 
of submaximal exercise capability with reduced carbohydrate oxidation. 
Metabolism 1983; 32:769-76. 
18. Phinney SD. Ketogenic diets and physical performance. Nutr & Metab 2004; 
1:2-10. 
19. Dashti HM, Mathew TC, Hussein et al. Long-term effects of a ketogenic diet in 
obese patients. Exp Clin Cardiol 2004; 9:200-5. 
20. Nickols-Richardson SM, Coleman MD, Volpe JJ et al. Perceived hunger is 
lower and weight loss is greater in overweight premenopausal women 
consuming a low-carbohydrate/high-protein vs. high-carbohydrate/low-fat diet. 
J Am Diet Assoc 2005; 105:1433-7. 
21. Kolotkin RL, Crosby RD, Williams GR, et al. Quality of life and obesity. Obes 
Rev 2001; 2:219-29. 
22. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus 
conventional weight loss diets in severely obese adults: one-year follow-up of 
a randomized trial. Ann Intern Med 2004; 140:778-85. 
23. Volek JS, Sharman MJ, Love DM et al. Body composition and hormonal 
responses to a carbohydrate-restricted diet. Metabolism 2002; 51:864-70. 
24. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A 
et al. Ketosis and appetite-mediating nutrients and hormones after weight 
loss. Eur J Clin Nutr 2013; 67:759-64. 
25. Dashti HM, Al-Zaid NS, Mathew TC, Al-Mousawi M, Talib H, Asfar SK. Long 
term effects of ketogenic diet in obese subjects with high cholesterol level. 
Mol Cell Biochem 2006; 286:1-9. 
26. Foster GD, Wyatt HR, Hill JO, Mc Gucket BG, Brill C, Mohammed BS, et al. A 
randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 
348:2082-90. 
27. Krieger JW, Sitren HS, Daniels MJ, Langkamp-Henken  B. Effects of variation 
in protein and carbohydrate intake on body mass composition during energy 
restriction: a meta-regression. Am J Clin Nutr 2006; 83:260-74. 
28. McClernon FJ, Yancy WS Jr, Eberstein JA, Atkins RC, Westman EC.  The 
effects of a low-carbohydrate ketogenic diet and a low-fat diet on mood, 
hunger, and other self-reported symptoms. Obesity 2007; 15:182-7. 
29. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J. A low-
carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 
2003; 348:2074-81. 
30. Ghosh S, Meister D, Cowen S, Hannan WJ, Ferguson A. Body composition at 
the bedside. Eur J Gastroenterol Hepatol 1997; 9:783-8. 
31. Sun SS, Chumlea WC, Heymsfield SB, Lukaski HC, Schoeller D, Friedl K. 
Development of bioelectrical impedance analysis prediction equations for 
body composition with the use of a multicomponent model for use in 
epidemiologic surveys. Am J Clin Nutr 2003; 77:331-40. 
32. Ashley JM, Herzog H, Clodfelter S, Vicki Bovee, Jon Schrage, Chris Pritsos. 
Nutrient adequacy during weight loss interventions: A randomized study in 
women comparing the dietary intake in a meal replacement group with a 
traditional food group. Nutr J 2007; 6:12-20. 
33. Veldhorst MA, Westerterp-Plantenga MS, Westerterp KR. Gluconeogenesis 
and energy expenditure after a high-protein, carbohydrate-free diet. Am J Clin 
Nutr 2009; 90: 519–526. 
34. Cahill Jr Gr. Fuel metabolism in starvation Annu Rev Nutr 2006; 26: 1–22. 
35. Nair KS, Welle SL, Halliday D, Cambell RG. Effect of β-hydroxybutyrate on 
whole-body leucine kinetics and fractional mixed skeletal muscle protein 
synthesis in humans. J Clin Invest. 1988;82:198–205 
36.  Layman DK, Walker DA. Potential importance of leucine in treatment of 
obesity and the metabolic syndrome. J Nutr. 2006;136:319S–23S 
37. Murphy KG, Bloom SR. Gut hormones and the regulation of energy 
homeostasis. Nature 2006; 444:854-9. 
38. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M. Butyrate improves 
insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 
58:1509-17. 
39. Kyriazis GA, Soundarapandian MM, Tyrberg B. Sweet taste receptor 
signalling in beta cells mediates fructose-induced potentiation of glucose-
stimulated insulin secretion. Proc Natl Acad Sci USA 2012; 109:E524-32. 
40. Harvie, M. "The effect of intermittent energy and carbohydrate restriction v. 
daily energy restriction on weight loss and metabolic disease risk markers in 
overweight women". British Journal on Nutrition. 2013; 110: 8: 13 
41. Abbasi J. Interest in the Ketogenic diet grows for weight loss and type II 
diabetes. JAMA, 2018; 319:215-217.  
 
 
 
Table 1: Comparisons of changes in outcome from Cycle 1 to Cycle 2 
Outcome  n Cycle 1 Cycle 2 Change Cycle 1 
to 2 (95% CI) 
P-value 
      
Weight  228 92.6  
[80.6, 111.0] 
89.3  
[77.5, 107.4] 
-3.7 [-4.2, -3.2] <0.0001# 
Waist circumference 227 104 [93, 115] 100 [90, 112] -3 [-4, -3] <0.0001# 
BMI 226 33.6  
[29.8, 37.8] 
32.4 
[28.9, 37.0] 
-1.3 [-1.5, -1.1] <0.0001# 
Fat mass 226 38.4  
[29.1, 46.3] 
34.6 
[27.5, 42.6] 
-2.8 [-3.1, -2.4] <0.0001# 
Lean mass 223 52.9 
[47.5, 65.2] 
52.3 
[46.9, 63.6] 
-0.8 [-1.1, -0.5] <0.0001# 
Phase angle 223 5.91 ± 0.78 5.89 ± 0.90 -0.02  
(-0.09, 0.05) 
0.58* 
Wellness marker 211 0.875 ± 0.022 0.876 ± 0.022 0.001 
(-0.001, 0.003) 
0.32* 
Dry lean mass 225 15.1 ± 4.2 14.9 ± 4.1 -0.1 (-0.2, -0.1) <0.0001* 
Water mass as a % of 
total body weight 
223 43.7 ± 5.2 44.6 ± 5.7 1.0 (0.7, 1.2) <0.0001* 
Statistics are: mean ± standard deviation plus mean change (95% confidence interval), or median [inter-
quartile range] plus median change [95% confidence interval] 
# P-value from Wilcoxon Signed-ranks test; * P-value from Paired t-test; ~ descriptive statistics presented 
on the patients with both Cycle 1 and Cycle 2 outcomes available 
 
 
Table 2: Comparisons of changes in outcome from Cycle 1 to Cycle 3 
Outcome  n Cycle 1 Cycle 3 Change Cycle 1 
to 3 (95% CI) 
P-value 
      
Weight  126 95.9 
[82.8, 115.7] 
89.6  
[78.4, 108.9] 
-6.4 [-7.3, -5.6] <0.0001# 
Waist circumference 125 107 [97, 118] 101 [91, 112] -6 [-8, -5] <0.0001# 
BMI 124 34.7  
[31.2, 38.7] 
32.8 
[29.0, 36.2] 
-2.4 [-2.8, -2.0] <0.0001# 
Fat mass 124 39.4 
[32.1, 46.3] 
34.3 
[27.2, 41.8] 
-4.9 [-5.8, -4.1] <0.0001# 
Lean mass 124 54.1 
[47.5, 69.1] 
52.4 
[46.6, 67.8] 
-1.3 [-1.6, -0.8] <0.0001# 
Phase angle 123 5.91 ± 0.87 5.77 ± 0.90 -0.13  
(-0.21, -0.05) 
0.002* 
Wellness marker 117 0.875 ± 0.022 0.878 ± 0.022 0.003 
(0.001, 0.006) 
0.02* 
Dry lean mass 124 15.1 ± 4.2 14.9 ± 4.1 -0.2 (-0.3, -0.1) 0.0002* 
Water mass as a % of 
total body weight 
124 43.1 ± 4.9 44.7 ± 5.9 1.6 (0.8, 2.4) 0.0001* 
Statistics are: mean ± standard deviation plus mean change (95% confidence interval), or median [inter-
quartile range] plus median change [95% confidence interval] 
# P-value from Wilcoxon Signed-ranks test; * P-value from Paired t-test; ~ descriptive statistics presented 
on the patients with both Cycle 1 and Cycle 2 outcomes available 
  
 
 
 
Table 3: Linear regression analysis examining how changes in study meaures were 
associated with percent change in weight  
 
Predictor Unadjusted linear regression Adjusted linear regression (*) 
n Regression 
coefficient  
p-value n 
 
Regression 
coefficient  
p-value 
(95% CI) (95% CI) 
Cycle 1 to 2       
Change in 
phase angle  
223 0.12 (-0.77, 1.01) 0.79 222 0.22 (-0.39, 0.83) 0.47 
       
Change in BMR 
/ weight 
222 -3.33 (-4.04, -2.61) <0.0001 222 0.37 (-0.54, -1.29) 0.42 
       
Cycle 1 to 3       
Change in 
phase angle  
123 0.67 (-1.18, 2.53) 0.47 121 -1.34 (-2.27, -0.40) 0.006 
       
Change in BMR 
/ weight 
124 -3.99 (-4.68, -3.29) <0.0001 121 -2.38 (-3.28, -1.47) <0.0001 
       
(*) Adjusted for change in waist circumference, change in fat mass, in addition to change in phase angle, 
change in BMR/weight 
 
Table 4  Complications/Side effects 
Number of patients  Complications/Side effects  
2 Diarrhoea  
4 Panic attack  
54 Asthenia  
1 Paroxysmal Tachycardia 
3 Difficult NG intubation 
1 Hyponatremia (patient with diabetes 
insipidus) 
 
10 Pharyngeal irritation 
1 Hypertension 
6 
 
 
Tube dislocation without further 
complications 
 
 
 
